BOCA RATON, Fla., June 27 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that Constance C. Bienfait
has been named vice president of investor relations. Ms. Bienfait brings over
27 years of investor and media experience to Nabi Biopharmaceuticals. Most
recently, she served as executive director of corporate communications for Kos
Pharmaceuticals, a New Jersey-based specialty pharmaceuticals company, where
she managed all aspects of the company's investor, public and government
relations and internal communications. Ms. Bienfait will assume the
responsibilities of Mark A. Soufleris, who has been appointed vice president
of marketing at Nabi Biopharmaceuticals.
"Connie brings with her extensive experience in the development and
execution of best practice investor relations strategies," stated Thomas H.
McLain, chairman, chief executive officer and president, Nabi
Biopharmaceuticals. "Her proactive approach will help Nabi Biopharmaceuticals
advance to its next level of success."
Prior to Kos Pharmaceuticals, Ms. Bienfait managed investor, media and
analyst relations at Viant Corporation, where she was the liaison between
Viant and sell-side analysts, institutional investors, media, shareholders and
Nasdaq. She also served as vice president at Morgen-Walke Associates, a New
York City investor and public relations consulting firm, where she advised
clients on all levels of strategic issues, crisis management, disclosure
requirements, as well as public, marketing and branding initiatives.
Ms. Bienfait attended the London School of Economics graduate program and
received her B.S. in Economics from Trinity College in Hartford, Connecticut.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. We are poised to capture large, commercial opportunities in our
four core business areas: Gram-positive bacterial infections, hepatitis,
kidney disease (nephrology), and nicotine addiction. We have three products on
the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune
Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a
number of products in various stages of clinical and preclinical development.
The company filed its Marketing Authorization Application in Europe for its
product candidate, StaphVAX(R) [Staphylococcus aureus Polysaccharide Conjugate
Vaccine], in December 2004. The application was accepted for review in
January 2005. StaphVAX is currently in a confirmatory Phase III clinical
trial in the U.S. StaphVAX is designed to prevent the most dangerous and
prevalent strains of Staphylococcus aureus bacterial infections. S. aureus
bacteria are a major cause of hospital-acquired infections and are becoming
increasingly resistant to antibiotics. The company's other products in
development include Altastaph(TM) [Staphylococcus aureus Immune Globulin
Intravenous (Human)], an antibody for prevention and treatment of S. aureus
infections, NicVAX(TM) [Nicotine Conjugate Vaccine], a vaccine to treat
nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an
antibody for preventing hepatitis C virus re-infection in liver transplant
patients. For additional information on Nabi Biopharmaceuticals, please visit
our website at: http://www.nabi.com .
This press release contains forward-looking statements that reflect the
company's current expectations regarding future events. Any such forward-
looking statements are not guarantees of future performance and involve
significant risks and uncertainties. Actual results may differ significantly
from those in the forward-looking statements as a result of any number of
factors, including, but not limited to, risks relating to the possibility that
our confirmatory Phase III clinical trial for StaphVAX or our plans to
commercialize StaphVAX in the European Union and United States may not be
successful; the possibility that we may not realize the value of our
acquisition of PhosLo; the company's ability to raise additional capital on
acceptable terms; the company's dependence upon third parties to manufacture
its products; the company's ability to utilize the full capacity of its
manufacturing facility; the impact on sales of Nabi-HB from patient treatment
protocols and the number of liver transplants performed in HBV-positive
patients; reliance on a small number of customers; the future sales growth
prospects for the company's biopharmaceutical products; and the company's
ability to obtain regulatory approval for its products in the United States or
abroad or to successfully develop, manufacture and market its products. These
factors are more fully discussed in the company's Annual Report on Form 10-K
for the fiscal year ended December 25, 2004 filed with the Securities and
Exchange Commission.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
CONTACT:
Mark Soufleris, Vice President, Investor &
Public Relations, Nabi Biopharmaceuticals, +1-561-989-5800
|
